Synergistic Effects of Silica Nanoparticles with Cisplatin in Ovarian Cancer Management: A Review
نویسندگان
1 Department of Pharmacology, Bukhara State Medical Institute named after Abu Ali ibn Sino. Bukhara, Uzbekistan
2 Tashkent State Technical University, Tashkent, Uzbekistan
3 School of Public Health, Tashkent Medical Academy, Tashkent, Uzbekistan
4 Department of Pathological Physiology, Samarkand State Medical University, Uzbekistan
5 Department of Fruits and Vegetables, Urganch State University, Uzbekistan
6 Department of Pharmacology, Bukhara State Medical Institute named after Abu Ali ibn Sino. Bukhara, Uzbekistan
7 Department of Pharmacology, Samarkand State Medical University, Samarkand, Uzbekistan
8 Department of Faculty and Hospital Surgery, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
9 Department of Propaedeutics of Children Diseases, Tashkent Medical Academy, Tashkent, Uzbekistan
10 Fergana Medical Institute of Public Health, Fergana, Uzbekistan
11 Department of Pediatrics, Fergana Medical Institute of Public Health, Fergana, Uzbekistan
12 Department of Oncology, Center for the Development of Professional Qualifications of Medical Workers, Tashkent, Uzbekistan
13 Department of Pharmacology, Bukhara State Medical Institute named after Abu Ali ibn Sino. Bukhara, Uzbekistan
doi
10.22052/JNS.2025.01.025چکیده
Ovarian cancer remains one of the most lethal gynecological malignancies, with high recurrence rates and chemoresistance posing significant clinical challenges. Cisplatin, a cornerstone chemotherapeutic agent, is limited by systemic toxicity, acquired resistance, and poor tumor targeting. Recent advances in nanotechnology offer promising strategies to enhance cisplatin’s therapeutic profile, with silica nanoparticles (SiNPs) emerging as a versatile platform for targeted drug delivery. This review explores the synergistic effects of SiNPs and cisplatin in ovarian cancer management, emphasizing their combined potential to overcome conventional treatment barriers. SiNPs’ unique properties—including biocompatibility, tunable porosity, and surface functionalization—enable improved cisplatin encapsulation, controlled release, and tumor-specific delivery via enhanced permeability and retention (EPR) effects. Preclinical studies highlight how SiNPs enhance cellular uptake, reduce off-target toxicity, and sensitize resistant ovarian cancer cells to cisplatin by modulating apoptotic pathways and the tumor microenvironment. Furthermore, co-delivery systems incorporating SiNPs and cisplatin demonstrate synergistic suppression of tumor growth in vivo, alongside improved pharmacokinetics. Despite these advances, challenges such as long-term biocompatibility, scalability, and regulatory hurdles remain critical barriers to clinical translation. This review synthesizes current evidence, underscores the mechanisms underlying SiNP-cisplatin synergy, and discusses future directions, including stimuli-responsive nanocarriers and combinatorial approaches with immunotherapy. By addressing these interdisciplinary opportunities, SiNP-cisplatin formulations hold transformative potential for personalized ovarian cancer therapy, offering a blueprint for enhanced efficacy and reduced adverse effects in oncology.
